← Leaderboards
Eric J. Stanbridge
University Of California Irvine
$1,337,072
Attributed
$1,337,072
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $360.3K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$1,337,072 · 3
By mechanism
R01$1,337,072 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California Irvine
Same institution · by research overlap
- Charles Joseph Gomer$5,568,369
- Gultekin Gulsen$4,437,348
- Christine M Gall$14,021,008
- David A Fruman$9,763,991
- Zhibin Guan$3,408,530
Others in their field
Top investigators on “Alleles”
- Richard A Gibbs · Baylor College Of Medicine$162,061,189
- Eric S Lander · Whitehead Institute For Biomedical Res$88,310,092
- Kc Kent Lloyd · University Of California At Davis$73,526,404
- Michael A Province · Washington University$68,289,985
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard J O'Reilly · Sloan-Kettering Institute For Cancer Res$51,945,604
Research focus
AllelesFibrosarcomaGene MutationBladder NeoplasmHeterozygoteAntisense Nucleic AcidProtooncogeneCarcinogenesisNeoplasm /Cancer GeneticsPhenotypeOligonucleotidesLaboratory MouseColon NeoplasmsGene TargetingPancreas NeoplasmsBiological ProcessBiological ModelsBiochemical PhenomenaBiochemicalAngiogenesisActivation AnalysisCellsCell SurvivalCell Line, Tumor
Grant awards (8)
Single Cell Analysis of Cross Talk Among Kinase Pathways$53,942
R01 · FY2007 · CA · contact PI
Single Cell Analysis of Cross Talk Among Kinase Pathways$305,279
R01 · FY2006 · CA · contact PI
Single Cell Analysis of Cross Talk Among Kinase Pathways$55,049
R01 · FY2006 · CA · contact PI
Single Cell Analysis of Cross Talk Among Kinase Pathways$311,601
R01 · FY2005 · CA
Single Cell Analysis of Cross Talk Among Kinase Pathways$44,991
R01 · FY2005 · CA
EVALUATION OF DOMINANTLY-ACTING RAS ONCOGENES$75,200
R01 · FY2001 · CA
EVALUATION OF DOMINANTLY-ACTING RAS ONCOGENES$269,732
R01 · FY2000 · CA
DOMINANT-NEGATIVE AND GAIN OF FUNCTION P53 MUTATIONS$221,278
R01 · FY2000 · CA